ASIP.org > PISA2017.org > Speaker Biographical Information

Brian Lehmann

Bio Narrative

Brian D. Lehmann Ph.D. is a Research Assistant Professor of Biochemistry at the Vanderbilt School of Medicine. Dr. Lehmann's research expertise lies at the intersection of cancer biology and bioinformatics. His unique understanding of both has led to the successful characterization of distinct molecular subgroups for triple-negative breast cancer (TNBC). These transcriptional subtypes display unique biology and sensitivity to standard chemotherapy and targeted therapies. Dr. Lehmann has advanced our understanding of androgen receptor signaling in breast cancer and is translating these discoveries to the clinic with collaborators in multi-institutional clinical trials. Together with colleagues, he has developed a novel population-based rearrangement algorithm and identified the targetable oncogenic fusions in FGFR3 and MERTK in TNBC. Dr. Lehmann's current research focuses on alterations that promote tumor cell escape from immune surveillance and promote immune suppression.

Title: New approaches to therapy in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is a heterogeneous collection of breast cancers that lack expression of estrogen receptor (ER), progesterone receptor (PR), and amplification of human epidermal growth factor receptor 2 (HER2). Unlike patients with ER-positive and HER2-amplified breast cancers, patients with TNBC have not seen an increase in survival or access to FDA-approved therapies outside of cytotoxic chemotherapy. While targeted therapy has been attempted in TNBC, biological and molecular heterogeneity has likely contributed to past failed clinical trials in unselected TNBC. The identification of transcription subtypes, rare activating mutations and rearrangements is now providing opportunities for targeted therapy in a subset of TNBC.